Treatment for primary biliary cholangitis (PBC), a common rare chronic autoimmune disease of the intrahepatic bile ducts, is frequently hampered by missed or delayed diagnosis as symptoms of PBC are often attributed to other conditions. This suboptimal recognition enables unchecked progression to end stage liver disease (ESLD), increasing patient mortality risk and negatively impacting quality of life. Clinical suspicion and investigation of key abnormal liver function tests represent a critical first step in optimized management. Similarly, identification of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), require practitioners to overcome clinical inertia and follow up on abnormal results from standard liver function tests to disrupt disease progression. Fortunately, recent FDA-approved agents and others in later stages of development are providing new and efficacious options for PBC and MASLD/MASH treatment. It is imperative that clinicians in collaboration with a multidisciplinary care team bridge diagnostic gaps and utilize novel emerging therapies for patients with PBC and MASLD/MASH.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-04-30 05:00:00
- End Date: 2025-04-30 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Gilead Sciences, Inc. - Amount: 0 - Is Kind Support: False Source: Ipsen - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine